The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Articles by Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Latest Updated Articles
Artificial Intelligence Drives Industry Response to Project OptimusPublished: February 27th 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Future-Proofing Clinical Trial Supply Chains Against Tariff Risks
2
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
3
Reframing the IND: From Tactical Requirement to Strategic Opportunity
4
Streamlining Trial Design to Accelerate Data Delivery and Investor Confidence
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
